ALG 903
Alternative Names: ALG-903Latest Information Update: 03 May 2026
At a glance
- Originator AliveGen
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 25 Feb 2026 Preclinical trials in Cancer in USA (unspecified route) prior to February 2026 (AliveGen pipeline, February 2026)